Adiponectin: An emerging cardiovascular risk factor. The REFERENCE study;Adiponectina, un factor de riesgo cardiovascular emergente. Estudio REFERENCE

Revista Espanola de Cardiologia

Volumn 61, Issue 11, 2008, Pages 1159-1167

  Barrios Alonso, Vivencio ^a   Gómez Huelgas, Ricardo ^b   Rodríguez, Rosario ^c   De Pablos Velasco, Pedro ^d   Madruga, F ^e   Velasco, E ^e   Gimenez R ^e   Rubio, J M ^e   Lopez J A ^e   Toril, J ^e   Ordonez A ^e   Yoldi, A ^e   Montagud, J B ^e   Pinar, J ^e   Fernandez M L ^e   Gomez R ^e   Sanchez A ^e   Martin J A ^e   Mateos, L ^e   Diaz J A ^e   Suarez M A ^e   Saban, J ^e   Arroyo, R ^e   Lopez J ^e   Fontanals, C ^e   Lopez A ^e   Marin R ^e   Chacon A ^e   Carretero, J F ^e   Hernandez C ^e   Perez L ^e   Villar, M R ^e   Villar, J R ^e   Gorgojo, J J ^e   Barroso, E ^e   Alvarez P ^e   Campillo, M ^e   Camafort, M ^e   Mazzanti, G ^e   Garre, J ^e   Morales, C ^e   Conde, F J ^e   Gomez P ^e   Fernandez F ^e   Suarez S ^e   Villarroel, M T ^e   Salgado, F M ^e   Egido, J ^e   Enjuto, J ^e   Gargallo, M A ^e   Garcia J A ^e   Azcona, L M ^e   Zamorano, J L ^e   Candel, I ^e   Serra, V ^e   Garcia A M ^e   De Luis, D ^e   Romero, E ^e   Guerra, J M ^e   Gomez F J ^e   Fuertes, J ^e   Daniel, C ^e   Gunther, S J ^e   Bellido, D ^e   Yanez J C ^e   Soto, F ^e   Rigueiro, P ^e   Garcia J M ^e   Diaz J L ^e   Sotres, G ^e   Rondan, J J ^e   Aziz, A ^e   Barriales, V ^e   Asensio, F ^e   Richard, J M ^e   Garcia S ^e   Rodrigo, A ^e   Perez J ^e   Ruiz, P ^e   Angel, J ^e   Gascuena R ^e   Ortiz, R ^e   Rayo, M ^e   Martinez E ^e   Gonzalez O ^e   Ortiz, A ^e   Gomez L F ^e   Donnay, S ^e   Melehi, D ^e   Horcajo, P ^e   Garcia F ^e   Gomez J ^e   Calderon A ^e   Fernandez M C ^e   Pujadas, R ^e   Rafael, J ^e   Alfani, O ^e   Virgos, G ^e   Elsaheb, M ^e   Recio, J ^e   Montull, S ^e   Abardia, X ^e   Sucunza, N ^e   Borrallo, R M ^e   Palos, M A ^e   Fernandez L A ^e   Arribas, J M ^e   Quintas, L ^e   Camacho, I ^e   Montes, P M ^e   Novales, J A ^e   Catalan J I ^e   Arteaga, R ^e   Ezcurdia, J ^e   Moreno, C ^e   Morillas, M ^e   Garcia H ^e   Ribas, M ^e   Ortiz, J ^e   Segura, I ^e   Soler, J ^e   Ripoll, T ^e   Fosch, J ^e   Moreno, R ^e   Domenech, M ^e   Antonio, M T ^e   Viguera, J ^e   Paytubi, C ^e   Blanch, P ^e   Cuatrecasas, G ^e   Gomez J M ^e   Laguna, A ^e   Mayos, J ^e   Lapuebla, M C ^e   Morales, A ^e   Silva, C ^e   Taberna, S ^e   Cordero, A ^e   Perez S ^e   Madariaga, I ^e   Elejalde, J I ^e   Ancin, R ^e   Tiberio, G ^e   Gracia, M L ^e   Berdun, M A ^e   Garcia A ^e   Gayan R ^e   Sanz, A ^e   Ferriz P ^e   Piedecausa, M M ^e   Toral, A ^e   Hernandez E ^e   Carnero, A ^e   Arribas, J ^e   Hernandez A ^e   Garcia B ^e   Gonzalvez M ^e   Martinez T ^e   Mediavilla, J D ^e   Fernandez C ^e   Romero, J A ^e   Gonzalez A ^e   Fajardo, R ^e   Ramos, E ^e   Aramburu, O ^e   Rivera, F J ^e   Arias, J L ^e   Beltran J ^e   Melguizo, I ^e   Mateos, P C ^e   Mendoza, M E ^e   Romero, S P ^e   Motero, J ^e   Guevara, J A ^e   Sanchez H ^e   Espino, A ^e   Varela, J M ^e   Lobon, J A ^e   Jimenez B ^e   Arizon J M ^e   Mora, J ^e   Pinero I ^e   Gaitan D ^e   Fernandez D ^e   Carmona, J R ^e   Garrido, A M ^e   Gomez J J ^e   Costo, A ^e   Alfredo, O ^e   Marcos, G ^e   Porras, Y ^e   Hernandez J ^e   Morales, J ^e   Perez J C ^e   Suarez M M ^e   Jimenez P ^e   Martinez F J ^e   more..

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c Centro de Investigation Basica Sanofi Aventis   (Spain)

^d UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^e NONE

Author keywords

Adiponectin; C reactive protein; Obesity; Vascular disease

Indexed keywords

ADIPONECTIN; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; WAIST CIRCUMFERENCE;

EID: 55849087597     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13127847     Document Type: Article

References (34)

1. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovás J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health. 2003;57:634-8.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-536.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-10.
4. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-7.
5. Marrugat J, Senti M. Why mortality from heart disease is low in France. High cholesterol may not have same effect on cardiovascular risk in southern Europe as elsewhere. BMJ. 2000;320:250.
6. Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003;24:1903-11.
7. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - Results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J. 2003;24:937-45.
8. Masia R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. J Epidemiol Community Health. 1998;52:707-15.
9. Menotti A, Lanti M, Puddu PE, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart. 2000;84:238-44.
10. Artaud-Wild SM, Connor SL, Sexton G, Connor WE. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. A paradox. Circulation. 1993;88:2771-9.
11. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovás J, Cordón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253-61.
12. Mostaza JM, Vicente I, Taboada M, Laguna F, Echániz A, García-Iglesias F, et al. La aplicación de las tablas del SCORE a varones de edad avanzada triplica el número de sujetos clasificados de alto riesgo en comparación con la función de Framingham. Med Clin (Barc). 2005;124:487-90.
13. Pyorala K. Assessment of coronary heart disease risk in populations with different levels of risk. Eur Heart J. 2000;21:348-50.
14. Palomer X, Pérez A, Blanco-Vaca F. Adiponectina: un nuevo nexo entre obesidad, resistencia a la insulina y enfermedad cardiovascular. Med Clin (Barc) 2005;124:388-95.
15. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
16. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-9.
17. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730-7.
18. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care. 2002;25:971-6.
19. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277:25863-6.
20. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057-63.
21. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975-81.
22. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85-9.
23. Salas-Salvado J, Granada M, Bullo M, Corominas A, Casas P, Foz M. Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome. Metabolism. 2007;56:1486-92.
24. Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA. Ethnic differences in adiponectin levels. Metabolism. 2004;53:1-3.
25. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - A new worldwide definition. Lancet. 2005;366:1059-62.
26. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
27. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
28. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-9.
29. Rothenbacher D, Brenner H, Marz W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J. 2005;26:1640-6.
30. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, et al. High molecular weight adiponectin as a predictor of longterm clinical outcome in patients with coronary artery disease. Am J Cardiol. 2007;100:569-74.
31. Kojima S, Funahashi T, Sakamoto T, Miyamoto S, Soejima H, Hokamaki J, et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart. 2003;89:667.
32. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46:459-69.
33. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425-8.
34. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.